Wacker doubles production area at biologics plant

Published: 8-Mar-2010
Manufacturing Research & Development Finance Pharmaceutical

Wacker Chemie officially opens its new biologics plant in Jena, Germany.

Wacker Chemie has officially opened its new production facility for pharmaceutical proteins, or biologics in Jena, Germany.

The firm says the expansion will enable it to meet growing demand for biologically manufactured pharmaceuticals used to treat cancer, multiple sclerosis and hepatitis, among other indications.

The expansion, together with a building for process development and quality control completed last year, brings the total investment at the plant to Euro 18m.

Wacker has almost doubled the production area at the GMP-certified site. A new facility for product purification also allows up to three times higher product yields per batch.

"Demand for advanced biotech products is growing worldwide. Innovative, biotechnological processes such as Wacker's ESETEC secretion system allow us to meet demand and continue to shape the developments in biotechnology here in Germany," said Auguste Williams, a member of Wacker's Executive Board.

"We now have an ideal system for developing the sophisticated processes and analytical techniques of modern, microbe-based biologics," added Thomas Maier, managing director of Wacker Biotech.

"This allows Wacker to optimise the entire process chain, from lab operations to industrial GMP production. Customers thus benefit from a full process and analysis package provided from a single source. And with the expansion of our production capacities, we can now make our innovative ESETEC secretion technology available to more customers."

Traditional production methods aside, the focus of the new unit is on Wacker's ESETEC and DENSETEC proprietary technologies, which enable simpler, more cost-efficient and high-yield production of biologics for the pharmaceuticals industry.



See more

You may also like

Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

Read more
The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines

Trending Articles

  1. 3PBIOVIAN and Colombia's National Cancer Institute partner to develop first locally produced oncology biosimilar The CDMO has signed an agreement with Colombia's Instituto Nacional de Cancerología to develop a biosimilar monoclonal antibody for an oncology indication, with technology transfer planned to enable domestic manufacturing
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Moving with speed and scale: innovative, material-sparing approaches to accelerate clinical development As early-stage drug development is often hindered by limited API supply, rising costs and tight timelines, material-sparing technologies are helping companies to progress faster with less
  3. Why weight sorting should move earlier in OSD development Phillip Ruda explains how earlier weight intelligence can improve process understanding, reduce risk and accelerate learning cycles

Upcoming event

DCAT Week

23–26 March 2026 | Conference | New York, US See all

You may also like

Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
Manufacturing

Clariant opens first US pharmaceutical-grade PEG excipient manufacturing site in Texas

Clariant has expanded its Clear Lake facility in Texas to produce GMP-compliant pharmaceutical-grade polyethylene glycol excipients, marking its first US-based manufacturing site for the products and strengthening supply chain resilience for North American and Latin American pharma customers
Design & Build

ESTEVE CDMO expands spray drying and high-potency containment capacity at Girona facility

ESTEVE CDMO has announced plans to add a 3000-square-metre production unit at its Celrà site in Spain to house additional spray drying equipment and high-potency containment suites, with the first new GEA spray dryer due online in Q1 2027
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Oncoinvent patent win and CellCarta deal highlight IP power in oncology innovation

New patent protection for Radspherin and a global exclusivity deal for Aspyre Lung underline how strong IP strategies are driving competitive advantage in cancer therapeutics and diagnostics
Research & Development

ProImmune and Roslin Institute collaborate to develop species-specific Ankyron binders for veterinary immunology

Immunological reagents specialist ProImmune has partnered with the University of Edinburgh's Roslin Institute to generate and validate novel species-specific binding proteins for porcine, bovine, avian and salmonid research, addressing a critical shortage of high-quality veterinary immunology reagents
Research & Development

Siemens Healthineers launches blood-based pTau217 and BDTau research assays for Alzheimer's and neurological disease

Siemens Healthineers has made two automated brain biomarker assays available for research use, offering scientists a less invasive blood-based alternative to cerebrospinal fluid testing for investigating neurological disease progression and early Alzheimer's detection
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Subscribe now